Shield Therapeutics (STX) Competitors

GBX 6.86 +0.11 (+1.63%)

As of 12:20 PM Eastern

STX vs. ELX, TAO, APC, DGI, and IDEA

Should you be buying Shield Therapeutics stock or one of its competitors? The main competitors of Shield Therapeutics include El Oro (ELX), TAO Alpha (TAO), Apc Technology Group (APC), DG Innovate (DGI), and Ideagen (IDEA). These companies are all part of the "computer hardware" industry.

How does Shield Therapeutics compare to El Oro?

El Oro (LON:ELX) and Shield Therapeutics (LON:STX) are both small-cap computer hardware companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

El Oro has higher earnings, but lower revenue than Shield Therapeutics. Shield Therapeutics is trading at a lower price-to-earnings ratio than El Oro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
El Oro	-£7.25M	0.00	N/A	-£2.50	N/A
Shield Therapeutics	£49.70M	1.47	-£36.28M	-£2.00	N/A

1.1% of Shield Therapeutics shares are held by institutional investors. 3.0% of Shield Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Shield Therapeutics had 1 more articles in the media than El Oro. MarketBeat recorded 1 mentions for Shield Therapeutics and 0 mentions for El Oro. Shield Therapeutics' average media sentiment score of 0.39 beat El Oro's score of 0.00 indicating that Shield Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
El Oro	Neutral
Shield Therapeutics	Neutral

Shield Therapeutics has a consensus target price of GBX 15, suggesting a potential upside of 118.66%. Given Shield Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Shield Therapeutics is more favorable than El Oro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
El Oro	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Shield Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

El Oro has a net margin of 0.00% compared to Shield Therapeutics' net margin of -34.53%. Shield Therapeutics' return on equity of 103.62% beat El Oro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
El Oro	N/A	N/A	N/A
Shield Therapeutics	-34.53%	103.62%	-47.85%

Summary

Shield Therapeutics beats El Oro on 11 of the 13 factors compared between the two stocks.

How does Shield Therapeutics compare to TAO Alpha?

TAO Alpha (LON:TAO) and Shield Therapeutics (LON:STX) are both small-cap computer hardware companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.

TAO Alpha has higher earnings, but lower revenue than Shield Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TAO Alpha	N/A	N/A	-£1.57M	N/A	N/A
Shield Therapeutics	£49.70M	1.47	-£36.28M	-£2.00	N/A

TAO Alpha has a net margin of 0.00% compared to Shield Therapeutics' net margin of -34.53%. Shield Therapeutics' return on equity of 103.62% beat TAO Alpha's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TAO Alpha	N/A	-128.73%	-64.09%
Shield Therapeutics	-34.53%	103.62%	-47.85%

Shield Therapeutics has a consensus target price of GBX 15, indicating a potential upside of 118.66%. Given Shield Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Shield Therapeutics is more favorable than TAO Alpha.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TAO Alpha	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Shield Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

0.7% of TAO Alpha shares are owned by institutional investors. Comparatively, 1.1% of Shield Therapeutics shares are owned by institutional investors. 98.3% of TAO Alpha shares are owned by insiders. Comparatively, 3.0% of Shield Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Shield Therapeutics had 1 more articles in the media than TAO Alpha. MarketBeat recorded 1 mentions for Shield Therapeutics and 0 mentions for TAO Alpha. Shield Therapeutics' average media sentiment score of 0.39 beat TAO Alpha's score of 0.00 indicating that Shield Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
TAO Alpha	Neutral
Shield Therapeutics	Neutral

Summary

Shield Therapeutics beats TAO Alpha on 10 of the 13 factors compared between the two stocks.

How does Shield Therapeutics compare to Apc Technology Group?

Apc Technology Group (LON:APC) and Shield Therapeutics (LON:STX) are both small-cap computer hardware companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Apc Technology Group has higher earnings, but lower revenue than Shield Therapeutics. Shield Therapeutics is trading at a lower price-to-earnings ratio than Apc Technology Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apc Technology Group	£19.20M	0.00	N/A	£0.50	N/A
Shield Therapeutics	£49.70M	1.47	-£36.28M	-£2.00	N/A

Apc Technology Group has a net margin of 0.00% compared to Shield Therapeutics' net margin of -34.53%. Shield Therapeutics' return on equity of 103.62% beat Apc Technology Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apc Technology Group	N/A	N/A	N/A
Shield Therapeutics	-34.53%	103.62%	-47.85%

Shield Therapeutics has a consensus target price of GBX 15, indicating a potential upside of 118.66%. Given Shield Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Shield Therapeutics is more favorable than Apc Technology Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apc Technology Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Shield Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

1.1% of Shield Therapeutics shares are owned by institutional investors. 3.0% of Shield Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Shield Therapeutics had 1 more articles in the media than Apc Technology Group. MarketBeat recorded 1 mentions for Shield Therapeutics and 0 mentions for Apc Technology Group. Shield Therapeutics' average media sentiment score of 0.39 beat Apc Technology Group's score of 0.00 indicating that Shield Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Apc Technology Group	Neutral
Shield Therapeutics	Neutral

Summary

Shield Therapeutics beats Apc Technology Group on 9 of the 13 factors compared between the two stocks.

How does Shield Therapeutics compare to DG Innovate?

Shield Therapeutics (LON:STX) and DG Innovate (LON:DGI) are both small-cap computer hardware companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations and risk.

DG Innovate has lower revenue, but higher earnings than Shield Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shield Therapeutics	£49.70M	1.47	-£36.28M	-£2.00	N/A
DG Innovate	£24.50K	0.00	-£4.91M	N/A	N/A

Shield Therapeutics currently has a consensus target price of GBX 15, indicating a potential upside of 118.66%. Given Shield Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Shield Therapeutics is more favorable than DG Innovate.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shield Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
DG Innovate	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

1.1% of Shield Therapeutics shares are held by institutional investors. Comparatively, 8.0% of DG Innovate shares are held by institutional investors. 3.0% of Shield Therapeutics shares are held by company insiders. Comparatively, 45.7% of DG Innovate shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Shield Therapeutics had 1 more articles in the media than DG Innovate. MarketBeat recorded 1 mentions for Shield Therapeutics and 0 mentions for DG Innovate. Shield Therapeutics' average media sentiment score of 0.39 beat DG Innovate's score of 0.00 indicating that Shield Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Shield Therapeutics	Neutral
DG Innovate	Neutral

Shield Therapeutics has a beta of 1.877, suggesting that its share price is 88% more volatile than the S&P 500. Comparatively, DG Innovate has a beta of 3.55, suggesting that its share price is 255% more volatile than the S&P 500.

DG Innovate has a net margin of 0.00% compared to Shield Therapeutics' net margin of -34.53%. Shield Therapeutics' return on equity of 103.62% beat DG Innovate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shield Therapeutics	-34.53%	103.62%	-47.85%
DG Innovate	N/A	-129.16%	-50.26%

Summary

Shield Therapeutics beats DG Innovate on 8 of the 14 factors compared between the two stocks.

How does Shield Therapeutics compare to Ideagen?

Ideagen (LON:IDEA) and Shield Therapeutics (LON:STX) are both small-cap computer hardware companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, media sentiment, profitability, risk and earnings.

Ideagen has higher revenue and earnings than Shield Therapeutics. Shield Therapeutics is trading at a lower price-to-earnings ratio than Ideagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ideagen	£75.28M	0.00	N/A	£0.02	N/A
Shield Therapeutics	£49.70M	1.47	-£36.28M	-£2.00	N/A

Shield Therapeutics has a consensus target price of GBX 15, indicating a potential upside of 118.66%. Given Shield Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Shield Therapeutics is more favorable than Ideagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ideagen	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Shield Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Ideagen had 1 more articles in the media than Shield Therapeutics. MarketBeat recorded 2 mentions for Ideagen and 1 mentions for Shield Therapeutics. Shield Therapeutics' average media sentiment score of 0.39 beat Ideagen's score of 0.00 indicating that Shield Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ideagen	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Shield Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

1.1% of Shield Therapeutics shares are held by institutional investors. 3.0% of Shield Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Ideagen has a net margin of 0.00% compared to Shield Therapeutics' net margin of -34.53%. Shield Therapeutics' return on equity of 103.62% beat Ideagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ideagen	N/A	N/A	N/A
Shield Therapeutics	-34.53%	103.62%	-47.85%

Summary

Shield Therapeutics beats Ideagen on 7 of the 13 factors compared between the two stocks.

Get Shield Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STX vs. The Competition

Export

Metric	Shield Therapeutics	Drug Manufacturers Industry	Medical Sector	LON Exchange
Market Cap	£73.29M	£1.61B	£6.25B	£2.77B
Dividend Yield	N/A	2.97%	2.78%	6.15%
P/E Ratio	-3.43	4.24	20.88	366.05
Price / Sales	1.47	1,458.94	533.46	88,619.87
Price / Cash	6.36	10.18	43.29	27.89
Price / Book	125.36	11.11	9.98	7.72
Net Income	-£36.28M	£20.70B	£3.54B	£5.89B
1 Month Performance	-19.29%	-0.01%	4.68%	4.08%
1 Year Performance	170.08%	24.78%	40.48%	89.87%

Shield Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STX Shield Therapeutics	1.6323 of 5 stars	GBX 6.86 +1.6%	GBX 15 +118.7%	+159.7%	£73.29M	£49.70M	N/A	40,000
ELX El Oro	N/A	N/A	N/A	N/A	£41.06M	-£7.25M	N/A	1,122
TAO TAO Alpha	N/A	GBX 7.10 +31.5%	N/A	+1,675.0%	£26.89M	N/A	N/A	3	Gap Up High Trading Volume
APC Apc Technology Group	N/A	N/A	N/A	N/A	£18.03M	£19.20M	19.75	164,000
DGI DG Innovate	N/A	N/A	N/A	N/A	£1.90M	£24.50K	N/A	790	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:STX) was last updated on 5/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Shield Therapeutics (STX) Competitors

STX vs. ELX, TAO, APC, DGI, and IDEA

How does Shield Therapeutics compare to El Oro?

Summary

How does Shield Therapeutics compare to TAO Alpha?

Summary

How does Shield Therapeutics compare to Apc Technology Group?

Summary

How does Shield Therapeutics compare to DG Innovate?

Summary

How does Shield Therapeutics compare to Ideagen?

Summary

Media Sentiment Over Time

STX vs. The Competition

Shield Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Shield Therapeutics (STX) Competitors

STX vs. ELX, TAO, APC, DGI, and IDEA

How does Shield Therapeutics compare to El Oro?

Which has stronger valuation and earnings, ELX or STX?

Do institutionals and insiders hold more shares of ELX or STX?

Does the media prefer ELX or STX?

Do analysts rate ELX or STX?

Is ELX or STX more profitable?

Summary

How does Shield Therapeutics compare to TAO Alpha?

Which has preferable valuation & earnings, TAO or STX?

Is TAO or STX more profitable?

Do analysts rate TAO or STX?

Do insiders and institutionals believe in TAO or STX?

Does the media favor TAO or STX?

Summary

How does Shield Therapeutics compare to Apc Technology Group?

Which has better valuation & earnings, APC or STX?

Is APC or STX more profitable?

Do analysts recommend APC or STX?

Do insiders and institutionals believe in APC or STX?

Does the media prefer APC or STX?

Summary

How does Shield Therapeutics compare to DG Innovate?

Which has stronger valuation & earnings, STX or DGI?

Do analysts rate STX or DGI?

Do institutionals and insiders believe in STX or DGI?

Does the media refer more to STX or DGI?

Which has more volatility & risk, STX or DGI?

Is STX or DGI more profitable?

Summary

How does Shield Therapeutics compare to Ideagen?

Which has preferable earnings and valuation, IDEA or STX?

Do analysts prefer IDEA or STX?

Does the media refer more to IDEA or STX?

Do insiders & institutionals have more ownership in IDEA or STX?

Is IDEA or STX more profitable?

Summary

Media Sentiment Over Time

STX vs. The Competition

Shield Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools